“Effectiveness of Erythropoiesis-Stimulating Agent Therapy with Oral and Intravenous Iron Supplementation in Achieving Hemoglobin Targets in Stage 5 Chronic Kidney Disease Patients”, JFM, vol. 9, no. 1, pp. 499–507, Oct. 2026, doi: 10.35451/jfm.v9i1.3691.